Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.14 AUD
Change Today -0.0025 / -1.75%
Volume 305.0K
As of 1:34 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.14
Previous Close
A$0.14
Day High
A$0.14
Day Low
A$0.14
52 Week High
04/20/15 - A$0.45
52 Week Low
11/19/14 - A$0.08
Market Cap
59.4M
Average Volume 10 Days
922.5K
EPS TTM
A$-0.03
Shares Outstanding
424.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited engages in the pharmaceutical research and development business in Australia. The company primarily has two drug technology platforms, which include superbenzopyran (SBPs) and anti-tropomyosin (ATMs). Its SBP technology platform offers Cantrixil, an intra-cavity anti-cancer agent for the treatment of ovarian cancer, malignant ascites, and malignant pleural effusion; and Trilexium for the treatment of brain cancers, neuroblastoma, and melanoma. Its ATM technology platform provides Anisina that destructs cancer cells cytoskeleton. The company is also developing various programs in the areas of regenerative medicine, facioscapulohumeral muscular dystrophy, and lysosomal storage disorder. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Acting Chief Financial Officer and Financial ...
Total Annual Compensation: A$34.7K
Company Secretary
Total Annual Compensation: A$57.5K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$279.0K
Director of ATM Program
Total Annual Compensation: A$52.5K
Degenerative Disease Program Director
Total Annual Compensation: A$32.8K
Compensation as of Fiscal Year 2014.

novogen ltd (NRT) Key Developments

Novogen Limited Announces Executive Changes

Novogen Limited announced the appointment to the Board of Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive. Mr. Ross, a former director of Novogen Limited will re-join the Board with immediate effect and take on the role of Acting Chief Executive until a permanent appointment is made. Mr. Ross is currently Chairman of Premier Veterinary Group PLC, a non-executive director of Amarantus Bioscience Holdings Inc. and a non-executive director for Anatara Lifesciences Ltd, Benitec Biopharma Ltd. and Tissue Therapies Ltd.

Novogen Limited Announces Resignation of Graham Kelly as Chief Executive Officer and Director

The Board of Directors of Novogen Limited advised that it has accepted the resignation of its Chief Executive Officer and Director, Dr. Graham Kelly, effective July 22, 2015. Dr. Kelly has decided to leave the Company to resume his work in non-oncology based early stage research.

Novogen Limited Announces Anisina Receives Orphan Drug Designation from FDA for Neuroblastoma

Novogen Limited announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. Orphan Drug Designation encourages the development of experimental drugs for clinical indications that do not have a high incidence and has been instigated in a number of territories including the U.S, Europe and Australia. Orphan Drug Designation can provide the following benefits to a drug developer: Eligibility for US government grants to defray clinical trial costs, Tax incentives for clinical research conducted in the United States, Waiver of US prescription drug filing fees and Enhanced marketing rights upon Market authorization. Anisina was granted Orphan Drug Designation for neuroblastoma under the U.S. Orphan Drug Act following a review by the FDA of a package of pre-clinical data submitted by Novogen. The data is from preclinical studies which were done as part of the Children’s Oncology Drug Alliance (CODA) involving Australian charity, The Kids’ Cancer Project (Sydney), The University of New South Wales (Sydney), The Nationwide Children’s Hospital (Columbus, Ohio), and Novogen. The key findings from these studies showed that Anisina significantly improved the effectiveness of the standard of care microtubule targeting compound, vincristine, in an animal model of neuroblastoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.14 AUD -0.0025

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.7x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.